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function decline
CPT Zachary Arthurs, MD,a LTC Benjamin Starnes, MD,b CPT Daniel Cuadrado, MD,a
CPT Vance Sohn, MD,a COL Howard Cushner, MD,c and COL(R) Charles Andersen, MD,b
Tacoma, Wash
Objective: The primary objective of this study was to analyze renal artery interventions performed at a tertiary medical
center and to evaluate improvements in hypertension and renal excretory function.
Methods: A retrospective analysis was performed of patients treated at a tertiary medical center from January 2001 to
December 2005. All patients treated with renal artery stenting by the Interventional Radiology or Endovascular Services
were included. Descriptive and inferential analyses were performed.
Results: Forty patients with renal artery stenosis were evaluated for renal artery stenting, of these 22 were followed up
with medical management. Twenty-six renal artery stents were placed in 18 patients (mean age, 70  8 years), of whom
76% were treated for multidrug resistant hypertension, and 24% were treated for renal salvage. Mean follow-up was 15
months. Patients experienced a significant reduction in hypertension and in the number of antihypertensive agents, but
this significance deteriorated at 6 months, when their blood pressure and number of medications returned to preproce-
dural values. Compared with a cohort that was followed up with medical management, the rate of renal function decline
improved from 0.08 mg/dL per month to 0.00 mg/dL per month (P < .05) after intervention. Patients with baseline
chronic renal insufficiency experienced the greatest benefit from renal artery stenting.
Conclusions: Renal artery stenting initially improves hypertension control, but the durability is lost after 6 months. Renal
artery stenting dramatically slows the rate of renal function decline and could potentially delay a patient’s requirement for
hemodialysis. ( J Vasc Surg 2007;45:726-32.)Hypertension resulting from renovascular stenosis has
been recognized for the past 70 years, but the appropriate
treatment of this disease has been plagued by inconsistent
results. Initial reports of nephrectomy for treatment of
hypertension implicated the diseased kidney as the etiology
of hypertension, but after nephrectomy, only 20% of pa-
tients remained normotensive at the 1-year follow-up.1
Goldblatt2 further focused attention on the kidney by
demonstrating hypertension in a canine model after nar-
rowing the renal artery.2 Through a series of experiments,
he suggested that a humoral mechanism was accounting for
the hypertensive effects, and later, renin was localized to the
juxtaglomerular cells of the kidney.3 After this period, oper-
ative revascularization was the mainstay of treatment, but
endoluminal treatment was soon to follow when Grüntzig
performed the first renal artery angioplasty.3
As endoluminal therapy progressed during the last 20
years, the treatment of renal atherosclerotic lesions shifted
from angioplasty to angioplasty and stenting. Two random-
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726ized controlled trials compared angioplasty without stent-
ing in the renal arteries with medical management, and
both failed to show a clinically relevant effect on blood
pressure and renal excretory function.4,5 The reinterven-
tion rate for assisted patency with angioplasty approaches
10% to 20% in the renal arteries, and this may contribute to
the lack of impact on blood pressure and renal function.
The initial surge of angioplasty and stenting of the renal
arteries was thought to remedy the high restenosis rate and
to potentially improve results.
Several series evaluate renal artery angioplasty with
stenting, but to our knowledge no randomized controlled
trials have compared renal artery stenting with best medical
management. The results are difficult to interpret given the
wide range of variability in outcomes. Several groups of
providers treat the disease, including primary care physicians,
internists, nephrologists, cardiologists, interventional radiolo-
gists, and vascular surgeons.
The purpose of this study was to examine the outcomes
for renal artery stenting at a tertiary medical center and to
evaluate patient selection for improvements in both hyper-
tension and renal excretory function.
METHODS
We performed a retrospective review of patients that
were presented at a Multidisciplinary Renovascular Confer-
ence, which included nephrologists, interventional radiol-
ogists, and vascular surgeons. Patients with atherosclerotic
renal artery disease were included between January 2001
and June 2006. Patients presented at this conference were
referred by nephrologists and internists for hypertension
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with simultaneous duplex ultrasound evidence of renal
artery stenosis. Renal ultrasound criteria reviewed were
velocity ratio, kidney size (cm), resistive index, and peak
systolic velocity (PSV).
The multidisciplinary team evaluated each patient for
potential renal artery stenting, and as a result, a cohort of
patients was followed up with medical management. The
reasons patients were not offered stenting included an
inadequate antihypertensive regimen, poor patient compli-
ance, acute medical conditions, resistive index 0.80, and
lesions that were70% stenosed. None of the criteria were
exclusive. Inadequate antihypertensive regimen was de-
fined by our nephrologist and most commonly consisted of
a patient that was on multiple low-dose medications. Other
patients were not taking angiotensin-converting enzyme
inhibitors or angiotensin-receptor blockers. Resistive index
was evaluated in the patient’s overall presentation but was
not used as absolute exclusion.
A retrospective chart analysis was performed of inpa-
tient and outpatient records. The patients who were not
offered stenting were followed up as a comparison with
those who did undergo stenting.
Initial screening of the renal vascular bed was per-
formed with duplex ultrasound criteria, and if the study was
noncontributory, magnetic resonance angiography (MRA)
was performed as a confirmatory test. The definitions for
reporting renal artery interventions were adapted from
Rundback et al.6
● Renal duplex criteria for a60% stenosis at an angle of
60° included a renal artery/aorta PSV ratio 3.5,
180 cm/s renal artery PSV, or a resistive index
difference of .15 between kidneys.
● MRA-detected renal artery stenosis were determined
by a ratio of the narrowest portion of the vessel to
reference vessel diameter.
● Hypertension was defined as a 6-month progression of
systolic blood pressure (SBP) 140 mm Hg or a
diastolic blood pressure (DBP) 90 mm Hg.
● Chronic renal insufficiency was defined as 6 months of
an elevated serum creatinine level 1.5 mg/dL.
● Ostial lesions were defined as lesions 1 cm of the
renal artery orifice.6
All renal artery stents in this cohort were considered a
technical success if30% residual stenosis after stent place-
ment was confirmed with postdeployment angiogram. An-
atomic placement of the stent with 1-mm to 2-mm projec-
tion into the aorta was the standard technique but was not
consistently recorded.
Outcomes for hypertension were defined as cure (DBP
90 mm Hg, SBP 140 mm Hg, and no medications),
improvement (DBP90 mm Hg, SBP140 mm Hg, the
same number or reduced number of medications, or DBP
reduction of 15 mm Hg on the same medications), and
failure (neither a cure or improvement).6 Blood pressure
and number of medications were recorded 1 month before
the procedure, at the time of the procedure, and then ateach follow-up visit. To express the dynamic trend of
patients’ hypertensive control with fluctuating medication
adjustments, we analyzed each variable of SBP, DBP, and
number of medications at each time interval after interven-
tion.
Outcomes of renal function were determined by plot-
ting the inverse creatinine slope over time using breakpoint
analysis.6,7 Inverse creatinine plots have been validated as a
measure for estimating progression of renal failure.8 Plot-
ting the inverse transforms the creatinine curve into a linear
relationship, and after this transformation, a slope can be
calculated by a least squares regression technique. Inverse
creatinine plots were created 24 months before the inter-
vention and then at each follow-up visit. Individual regres-
sion plots were performed to evaluate the response to
treatment, and then mean values of slope were taken for
group analysis. Clinical events included progression to he-
modialysis, nonfatal myocardial infarction, and death.
Time sensitive values were recorded 2 weeks of the
month and 2 months of the year for each time interval
recorded. For the medically managed patients, the time
analogous to intervention was the date at which they were
discussed for potential intervention.
RESULTS
The Multidisciplinary Team evaluated 40 patients: 29
renal artery stents were placed in 18 patients, and 22
patients were followed up with medical management. Base-
line characteristics were similar between the two groups
(Table I). The renal artery stent group had a higher pro-
portion of patients with baseline renal insufficiency and
slightly higher systolic blood pressures.
Initial ultrasound evaluations were similar between the
two groups (Table II). No significant differences existed in
ultrasound measurements, and the difference between the
percentage of patients with resistive index 0.8 was not
significant. Nine patients in the medical treatment group
underwent MRA, and the study failed to confirm the renal
artery lesion to be 60% in five of the patients. Four
patients in the renal artery stent group underwent MRA,
and all four had confirmed stenoses.
All 29 renal artery stenting procedures were considered
successful. No major procedure-related events (acute throm-
bosis, dissection, renal failure, rapid renal function decline, or
hemorrhage) or procedure-related deaths occurred. Three
patients experienced restenosis in the follow-up period, equat-
ing to a mean patency of 110 months (95% confidence interval
[CI], 99 to 121 months; Fig 1). Two patients were treated
with angioplasty, and one required angioplasty and stenting.
When we evaluated the impact on hypertension by
standardized reporting guidelines, no patient experienced a
cure. Only one patient with a renal artery stent met criteria
for an improvement in hypertension, and the rest were
categorized as failures.
A paired analysis was performed from each point of
follow-up back to the patients’ preprocedural values (Table
III) for SBP, DBP, and number of antihypertensive medi-
cations. No significant changes were found in blood pres-
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group. In the patients treated with renal artery stenting, the
median number of medications initially dropped from 3.5 to
1.0 at the 1-month follow-up. At the 3-month and 6-month
Table I. Cohort demographics
Characteristic*
RAS
n (%)
Medical
treatment
n (%) P
Patient total 18 22
Age, years 72  9 67  13 .518
Risk factors
Hypertension 18 (100) 22 (100) —
Hypercholesterolemia 14 (82) 16 (73) .479†
Diabetes 5 (29) 6 (27) .883†
Smoker .249†
Current 6 (35) 3 (14)
Remote history 2 (12) 5 (23)
Vascular disease:
CAD 8 (47) 11 (50) .855†
CVD 5 (29) 6 (27) .883†
PVD 6 (35) 8 (36) .945†
Antihypertensive medications:
-blocker 14 (93) 16 (73) .116†
ACE 8 (53) 13 (59) .729†
ARB 6 (40) 9 (43) .864†
Diuretic 9 (60) 15 (68) .609†
Creatinine (mg/dL) 1.5 1.0 .05‡
Chronic renal insufficiency 9 (52) 5 (22) .091†
SBP (mm Hg) 162  17 142  21 .05
DBP (mm Hg) 75  13 73  13 .959
Number taken 3.5 4.0 .420‡
Bilateral renal artery
stenosis 11 (61) 12 (46) .899†
Previous stent 1 (5.9) 4 (18) .363†
RAS, Renal artery stenting; CAD, coronary artery disease; CVD, cerebro-
vascular disease; PVD, peripheral vascular disease; ACE, angiotensin con-
verting enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic
blood pressure; DBP, diastolic blood pressure.
*Continuous data are presented as mean  standard deviation; categoric
data as n (%).
†Pearson 2 test, Fischer exact where appropriate.
‡Mann-Whitney U test, and measure of central tendency reported as me-
dian.
Table II. Ultrasound measurements
Measurement
(mean  SD)
RAS
(n  18)
Medical treatment
(n  22) P
Length (cm) 11.6  0.8 10.0  0.3 .627
AoPSV (cm/s) 86  9 82  20 .391
PSV (cm/s) 357  39 276  74 .288
PSV/AoPSV ratio 4.7 3.7 .478*
Resistive indices 0.75  0.02 0.72  0.04 .947
Resistive index
0.8 (%) 8 (44) 7 (32) .480†
RAS, Renal artery stent; AoPSV, aortic peak systolic velocity; PSV, peak
systolic velocity.
*Mann-Whitney U test, and measure of central tendency reported as me-
dian.
†Pearson 2 test, Fischer exact where appropriate.follow-up periods, the median number of medications in-creased to 3.0. At the 12-month follow-up visit, the number
of antihypertensive medications was not significantly altered
compared with preprocedural values. The SBP pressure was
only significantly altered at the 3-month follow-up visit. Fur-
ther analysis was performed comparing patients with unilateral
and bilateral stenosis as well as stratifying patients with chronic
renal insufficiency. The results were the same: the durability of
the procedure was lost at 6 months.
To evaluate the impact on renal function, we plotted
the inverse creatinine concentration vs time (Fig 2).
When the 2-year period before intervention was evaluated,
patients who were selected for renal artery stenting were
experiencing a more rapid rate per month (0.08 mg/dL)
of decline than patients who were not stented (0.03
mg/dL). After renal artery stenting, patients experienced a
significant (P  .05) plateau in their renal function com-
pared with their preprocedure slope; whereas, the medically
followed up group continued at the same rate of decline
during the follow-up period.
Patients treated with renal artery stenting were then
stratified by resistive indices, unilateral or bilateral disease,
and baseline chronic renal insufficiency. No significant dif-
ference was found in the per-month postintervention in-
verse creatinine slope for patients with a resistive index
0.8 (0.04 mg/dL) compared with a resistive index 0.8
(0.05 mg/dL). Patients with unilateral disease experienced
a per-month postprocedural slope of 0.00 mg/dL, and
those with bilateral disease had a slope of 0.02 mg/dL.
This difference was not significant. The patients with base-
line chronic renal insufficiency experienced the greatest
benefit, with a per-month postprocedural slope of 0.03
mg/dL compared with 0.03 mg/dL for those patients
without renal insufficiency (P  .05).
Within this cohort, no patient progressed to require
hemodialysis during a mean follow-up period of 15
months. One patient had a stroke 2 years after renal artery
Fig 1. Kaplan-Meier Curve for primary patency among all pa-
tients treated with stenting. The vertical line represents the point at
which error exceeds 10%.stent placement. The most common event in the follow-up
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patients with and without stents experienced an event-free
survival of 78 months (95% CI, 55 to 100 months) and 79
months (95% CI, 68 to 90 months), respectively. Renal
artery stenting was evaluated by Cox regression and did not
have a significant impact on myocardial events in the
follow-up period (hazard ratio (HR), 0.338; CI, 0.069 to
1.668; P  .183). None of the medically followed up
patients died. Mean survival was 104 months (95% CI, 84
to 124 months) for stented patients (Fig 4). Cox regression
showed that renal artery stenting did not significantly im-
pact mortality (HR, 0.016; CI, 0 to 15.16; P  .616).
DISCUSSION
Our primary finding in this review is that renal artery
stenting conducted in a environment influenced by multi-
ple medical disciplines can slow the rate of renal function
decline in patients with atherosclerotic renal artery stenosis.
In patients with baseline renal insufficiency, this effect was
profound.
Ischemic nephropathy may be the cause of end-stage
renal disease, but commonly these patients are diagnosed
with diabetic or hypertensive nephropathy. This etiology is
Table III. Hypertension outcomes during the follow-up p
Variable 0 1 3
Medical treatment
SBP* 142  21 151 20 152  12
DBP* 73  13 70  12 73  8
Meds, n† 4 4 4
RAS
SBP* 162  17 151  37 148  21**
DBP* 75  13 74  15 80  15
Meds, n† 3.5 1‡ 3‡
SBP, Systolic blood pressure (mm Hg); DBP, diastolic blood pressure (mm
*Paired t test analysis.
†Wilcoxon signed ranks test.
‡P  .05.
Fig 2. Inverse serum creatinine plot vs months of follow-up.
RAS, Renal artery stenting.potentially reversible and could reverse the progression toocclusion, loss of renal parenchyma, and hemodialysis.9,10
The renal arteries of these patients are typically evaluated
only after they have developed hypertension refractory to
medical management. Of patients 50 years old who are
referred for end-stage renal disease, 14% to 41% are found
to have a significant renal artery lesion.11,12 Depending on
the response rate, early intervention with renal artery stent-
ing has the potential to reduce the number of patients
progressing to hemodialysis annually.
Measurements of declining renal function have typi-
cally been a 20% change in serum creatinine level at each
follow-up visit, and reports for stenting have ranged from
“no benefit” to “loss of durability” to “a significant im-
provement.” This reporting method does not take into
account the variability of the serum creatinine level with
d
Time (months)
6 12 24 36 48
2  12 136  13 146  26 117  12 137  37
2  16 69  15 73  14 66  15 78  28
4 4 4 4 4
1  23 152  22 146  10 167  27 166  30
8  8 78  8 76  9 78  13 80  20
3‡ 4 4 4 4
Meds, medications; RAS, renal artery stent.
Fig 3. Kaplan-Meier curves for freedom from nonfatal myocar-
dial events. The solid line represents patients with renal artery
stents, and the hashed line represents patients followed up with
medical management. The vertical line denotes the time at which
error is 10%, which is at the same location for both curves.erio
13
6
17
7
Hg);time and gives little information about rate of progression
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curve as a way to evaluate renal function over time both
before and after intervention. Watson et al7 used this
method to demonstrate a dramatic improvement in renal
function, with either stabilization or improvement in all
surviving patients. Harden evaluated patients only with
advanced renal dysfunction (3 patients were receiving he-
modialysis) and found a high follow-up mortality (median
survival, 22 months) and a 78% improvement in renal
function. Watson evaluated all patients presenting with
renal artery stenosis and found that 100% of patients expe-
rienced a favorable improvement in their renal function.
In the present study, no patient experienced immediate
worsening of renal function, defined as a more negative
inverse creatinine slope. During the mean 15-month
follow-up, all patients benefited from renal artery stenting
by slowing the rate of renal function decline. Although the
magnitude of benefit for patients appears to be larger for
patients with existing baseline renal insufficiency, the pa-
tients with a serum creatinine level of 1.5 mg/dL also
responded favorably compared with their baseline. Some
studies have suggested that patients with bilateral disease
have an improved response. We identified a trend for
improvement in patients with bilateral disease, although
this was not significant.
Radermacher et al14 have reported that patients with
resistive index .80 do not experience improvement in
blood pressure or renal function after renal artery angio-
plasty alone.14 These data have been used as a selection
criteria for patients to undergo renal artery stenting, but in
our results, the resistive index did not have a significant
impact on the patients’ improvement after stenting. The
difference may be attributable to the inherent differences in
Fig 4. Kaplan-Meier survival curve. The solid line represents pa-
tients with renal artery stents, and the hashed line represents
patients followed up with medical management. The vertical line
represents the time at which error 10%.angioplasty vs stenting. In Radermacher’s evaluation, thepatients with a resistive index 0.80 experienced a decline
in their creatinine clearance during the follow-up period,
but the creatinine clearance was never plotted for time
period leading up to intervention. Although these patients
were categorized as failures, the rate of their decline may
have improved over time. Rocha-Singh et al15 also demon-
strated an improvement or stabilization of renal function
after renal artery stenting irrespective of resistive indices.
The resistive index is a measure of the underlying
chronic parenchymal disease, but it does not seem to abso-
lutely identify patients that may respond to endoluminal
treatment of renal artery stenosis. In our evaluation, no
patient progressed to hemodialysis, but by demonstrating
an improvement in the rate of decline, we expect to delay
hemodialysis therapy.
The outcome of blood pressure measurement is not
significantly altered by renal artery stenting. One random-
ized controlled trial comparing renal artery angioplasty
without stenting with best medical management was not
able to show a clinically significant alteration in blood
pressure management at 6 to 12 months postprocedure.5
There are no randomized trials for angioplasty with stent-
ing. Several retrospective analyses exist with various results,
but none are able to document a high cure rate.16-22 Nearly
all patients require medical management after their proce-
dure, and this is analogous with our results.
Patients typically have a dramatic blood pressure re-
sponse immediately after renal artery stenting. They may
initially wean off all their medications, but at each follow-up
visit, their blood pressure continues to rise, requiring the
resumption of antihypertensive therapy. Like previous ret-
rospective studies, the durability of the stent for hyperten-
sive control is lost. The fact that these patients do respond
initially implicates the renal artery in their hypertensive
management. The reason for failure was initially thought to
be due to high restenosis rates with angioplasty alone, but
now stenting is essentially able to approach a near 99%
secondary patency rate.17,23 With stenting, hypertension
control returns to baseline only after a short period, even
when stratified for patients with unilateral or bilateral dis-
ease. Further investigation will be required to delineate the
physiologic impact of dilating the renal artery and to deter-
mine why this response is lost over time. Using the indica-
tion of multi-drug hypertension as a sole indication for
intervention should be cautioned.
This study is limited by a small cohort size and a
retrospective analysis. The medically managed patients
were not true controls but instead were selected compari-
sons that were identified by a conference of specialists
making a comprehensive decision not to treat those pa-
tients. We attempted to create a weight-based formula for
each antihypertensive medication, but the difference in
dosing regimens, brands, and classes of medications made
this task impossible. Given the small number of patients, we
were unable to establish an impact on cardiac events or
mortality after intervention.
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This study confirms that renal artery stenting can be
performed with a nearly negligible periprocedure compli-
cation rate, and 100% assisted patency can be obtained. In
patients undergoing intervention for hypertension, the
benefit is only transient, but renal function significantly
improves with renal artery stenting.
The etiology of renal disease is multifactorial, involving
systemic lipid disorders, increasing age, segmental glomer-
ulosclerosis, fibrosis, hypertensive nephropathy, endothe-
lial dysfunction, and diabetic nephropathy. Renovascular
disease is just one factor that when reversed with renal
artery stenting has the potential to delay progressive loss of
renal function over time. The ability to arrest this progres-
sion has not been established. Further randomized con-
trolled trials will be needed to determine the impact on
hemodialysis, cardiac events, and mortality.
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Dr R. Eugene Zierler (Seattle, Wash). This report from the
Madigan Army Medical Center adds to the growing body of
evidence that documents the results of percutaneous interventions
for atherosclerotic renal artery disease. Despite lingering concerns
over the efficacy and durability of renal artery stenting, the favor-
able early technical results of catheter-based interventions, and the
relatively high risks of open surgery in the atherosclerotic patient
population, have made the less-invasive approach overwhelmingly
preferred. In fact, renal artery bypass surgery in this setting has all29 renal artery stents in 18 patients, I suspect that the correspond-
ing number of open renal artery operations was even lower. Look-
ing at outcomes in terms of hypertension and renal function, the
main conclusion is that improvement in blood pressure control was
transient; however, the rate of decline in renal function was signif-
icantly better than in a similar cohort of patients followed without
intervention.
Since the indications for intervention in this study are listed as
drug-resistant hypertension in 77% and renal salvage in 23%, this
suggests that only a minority of the patients (that is, 23% or about
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and timing are the key factors in maximizing benefit and minimiz-
ing both the risk and cost of intervention. The results of this study
focus our attention on the level of renal function and rate of renal
function decline. Other clinical features that may correlate with
outcome include kidney length (renal atrophy), severity of renal
artery stenosis, unilateral or bilateral renal artery disease, and renal
resistive index or other measures of parenchymal blood flow. With
that in mind, I have the following questions:
Number one, experience suggests that there is a “window of
opportunity” for renal revascularization in preservation of renal
function. Other than rate of decline in renal function, what factors
would you take into account when selecting patients with renal
insufficiency for renal artery intervention?
Number two, some hypertensive patients do appear to benefit
from renal revascularization, although this was not shown in your
study. Why do you think this patient group failed to respond to
intervention? Are there any situations in which you would still
recommend renal artery intervention for hypertension alone?
Number three, the manuscript mentions that nine of the
patients followed without intervention underwent renal MRA, and
a renal artery stenosis of 60% was not confirmed in five. Was the
initial diagnosis of renal artery stenosis in these patients made by
duplex ultrasound? If this is the case, can the authors comment on
this apparent discrepancy between these two imaging methods?
I appreciate the opportunity to review and discuss this paper.
Dr Zachary Arthurs. Thank you, Dr Zierler. The first ques-
tion is a question we are working through right now. Who are the
patients that are responders and who should we treat? The rate of
decline and the window of opportunity is something that we are
now looking for and hopefully we can randomize these patients
based on the indication for renal salvage. The point at which to
intervene we do not know.
The factors that we look for that are appealing are the fact that we
have now realized that the kidney obviously has humoral function.
The impact of the renal angiotensin has well been defined with split
renal function and its potential to damage a kidney with unilateral
renal artery stenosis. The endothelium also has endocrine function
impacting blood pressure control, and now the natriuretic peptides
released from the heart are recognized as having an endocrine role. All
these factors may play a role in renal artery hypertension. Maybe
measuring natriuretic peptide could give the clinician a marker along
with LVH that the patient’s heart is attempting to respond to volume
overload caused by a renal artery lesion. This is one of the measures
that we would like to explore. We have not yet defined the percentage
of renal function decline that should be treated with renal artery
stenting. I think it is an excellent point.
The concept of why did the hypertensive patients fail. I think
that is what was most intriguing to me. Many of these patients are
not taking any antihypertensive medications after their procedure,
but progressively the medications are returned as their hyperten-
sion returns. This suggests that maybe there is another humoral or
neural mechanism that allows an initial response but over time the
kidney fails once again. The kidney may lose its auto feedback
mechanisms, or it may be progression of underlying parenchymal
disease. I do not have a real good answer to explain that initial
transient response.
At this point I should recognize the fact that Dr Zierler,
having dedicated so much time to the vascular laboratory, would
have picked out the four discordances in MRA versus duplex and I
did not look at those specifically. If there was a patient that was felt
to maybe be poorly compliant, maybe could have gone up on their
medications and the lesion was borderline on ultrasound, those
were the patients that we would get a confirmatory study. If the
MRA was either borderline or less than our ultrasound, we would
use that to watch that patient and attempt medication control.
Dr James Watson (Seattle, Wash). You just answered one of
my questions but I am curious as to what are the current indica-
tions for renal artery intervention at Madigan, and who will you
intervene on when you see this patient in clinic?Dr Arthurs. We are becoming extremely cautionary for inter-
vening for hypertension as a sole indication and we are looking at
evaluating a series of patients who are randomized based on their
rate of renal function decline.
DrFredWeaver (Los Angeles, Calif). I may have missed it but
did you provide any numbers with regard to immediate technical
success of your stenting procedures?
DrArthurs. I left that out completely because there was 100%
technical success at the time of the procedure and we had no
periprocedural morbidity associated with regards to acute throm-
bosis, embolization, dissection or groin complications in this small
series.
Dr Weaver. Do you have any follow-up data with regards to
restenosis?
Dr Arthurs. At the 3 and 6-month mark, we have docu-
mented imaging for restenosis, and I do have a restenosis slide in
the manuscript, but it is roughly the same across the cohort of 78%
with 100% secondary patency.
Dr Weaver. The observation that the hypertensive improve-
ment deteriorates after a year has been made by a number of
authors, as you know. The University of Rochester reported a large
series where at 5 years, the hypertension benefit deteriorated over
the 5-year followup despite the fact that 100% of the renal artery
stents were patent. With regards to renal function, do you use any
renal protection when you do these procedures, either embolic
protection or CO2, to minimize renal damage? As you know, with
renal stenting, renal function actually deteriorates in a significant
number of patients. Either the iodinated contrast and/or choles-
terol embolization from the plaque is hypothesized as the culprit.
What are your thoughts on renal protection?
Dr Arthurs. Periprocedural data were limited, but no protec-
tion devices were used. There were cases that required adjunctive
measures such as lytic therapy.
Dr Wesley Moore (Los Angeles, Calif). As Dr Zierler indi-
cated in his discussion, with the availability of stent balloon angio-
plasty, there was a rapid transition from direct surgical repair to this
technique with the assumption that the two were equivalent. I
think that we ought to take a hard look at whether or not they
really are equivalent. I wonder if you had the opportunity to
compare the data that you have presented with earlier surgical
experience. My recollection is that the cure or improved rate using
the same parameters that you have described as about 75% over
long periods of time when direct surgical reconstruction of the
renal artery was carried out. In view of your results and the results
reported from UCSD this morning, I wonder if we ought to
reconsider whether or not the two are equivalent and consider at
the risk of being considered a surgical dinosaur maybe we ought to
start looking again at direct renal surgical repair.
Dr Arthurs. Sir, I agree completely. It is hard for me to see
how we transitioned to where we have. There is only one paper that
I know of that has a comparison of medical management to
operative revascularization, and that was in 1973. A large propor-
tion of patients had fibromuscular dysplasia, only about 40 patients
in each group, and they were able to show a benefit with regard to
blood pressure and creatinine. They also had extremely long
follow-up, 10 years. It suggested that there was a survival benefit as
compared to medical management. What you sacrifice is a periop-
erative mortality rate associated with surgery, but that is the only
study I know that is medical management compared to surgery.
Then we made the leap to angioplasty. To echo Dr Schneider’s
words at this conference, once you go to endoluminal therapy, the
endoluminal problems are fixed with another endoluminal ther-
apy. Once angioplasty was known to have a high restenosis rate, an
acute thrombosis rate, and a learning curve, instead of going back
to surgery we went on to stents. Now, we utilize primary stents
primarily in the renal artery. The comparisons of angioplasty to
surgery are really marginal and then we do not have any studies
with renal artery stenting versus medical management or stenting
versus surgery for that matter. It would take a well-designed
randomized controlled trial to define these differences in outcome.
